HC Wainwright & Co. Maintains Buy on Genmab, Lowers Price Target to $38

Benzinga Newsdesk www.benzinga.com Negative 52.8%

Neg 52.8% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $40 to $38.